Allergan Settles InnoPharma Patent Suit Over Restasis

Allergan will grant InnoPharma licenses to manufacture a generic version of Restasis in the United States beginning Feb. 24, 2024.

Oct. 12, 2017

Dublin-based Allergan announced that it has reached an agreement with InnoPharma Inc. to settle patent litigation regarding its patents covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%. The patents are listed in the Orange Book and expire on August 27, 2024.

Allergan will grant InnoPharma licenses to market a generic version of Restasis in the United States beginning on Feb. 24, 2024, or earlier in certain cases. Also, under special circumstances, Allergan will authorize InnoPharma to launch an authorized generic version of Restasis on Aug. 28, 2024.